Company Presentations: September 2022 | Market Screeners

Strengthening the standard of care for retinal disease by working to achieve the first FDA approval of bevacizumab in ophthalmology

Disclaimer

This presentation contains forward-looking statements regarding Outlook Therapeutics, Inc. (“Outlook Therapeutics” or the “Company”), which are based on management’s current expectations and which include known and unknown uncertainties. Subject to certainty and risk. “anticipate”, “believe”, “estimate”, “expect”, “start”, “intend”, “could”, “plan”, “seek”, “target” , words such as “will,” and variations thereof These words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, among other things, the potential for ONS-5010 as the first FDA-approved ophthalmic formulation of bevacizumab-vikg; our expectations for market exclusivity of ONS-5010; Includes statements regarding potential and timing of commercial launch. ,ONS-5010’s Ability to Replace and Address Avastin Off-Label Use Issues, Other Drug Candidates in Development, Commercial Drivers and Potential for ONS-5010, Successful Ongoing ONS-5010 Trials in Wet AMD , ONS planned trials-5010 DME and BRVO, adequacy of our capital resources, and other statements that are not historical facts. Our actual results will depend on a number of factors, including, but not limited to, the risks inherent in developing drug candidates, conducting successful clinical trials, obtaining regulatory approval and our ability to raise additional funding. may differ significantly from those discussed. Equity and debt financing on favorable terms, among other risk factors. These risks are discussed in more detail under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2021 and is supplemented by its quarterly report on Form 10-Q. , 2022, and other filings with the Securities and Exchange Commission. Additionally, Outlook Therapeutics operates in a highly competitive and rapidly changing environment. New risks arise from time to time. It is not possible for our management to anticipate all risks and the effect that all factors may have on our business, or any factor or combination of factors, may cause the actual results to differ from those contained in futures contracts. Nor can we assess the extent to which it is likely to be significantly different. -Visible statement. Moreover, such risks may increase as a result of the ongoing COVID-19 pandemic. In light of these risks, uncertainties and assumptions, the forward-looking statements made in this presentation may not occur and actual results may differ materially from those anticipated or implied. There is a possibility.

Neither Outlook Therapeutics nor any other person assumes responsibility for the accuracy or completeness of any forward-looking statements, except as required by law. The Company is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise. This presentation contains trademarks, registered trademarks and trade names of Outlook Therapeutics and other companies. All such trademarks, registered trademarks and trade names are the property of their respective owners.

Leadership Team: Global Ophthalmic Development and Launch Excellence

investment highlights

US FDA BLA submission for ONS-5010 (bevacizumab-vikg)1 Investigative Therapies for the Treatment of Wet AMD

Targeting the $13.1 billion global ophthalmic anti-VEGF market2

AMD = age-related macular degeneration; DME = diabetic macular edema; BRVO = branch retinal vein occlusion